Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Carfilzomib in Relapsed/Refractory Mantle Cell Lymphoma
NCT02269085Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2015
- Primary completion
- May 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ibrutinib and carfilzomib in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose of Carfilzomib When Given With Ibrutinib at 28 days. Started Apr 2015; status: terminated.
02
Drugs
ibrutinibcarfilzomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02269085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269085.